Epoprostenol (Flolan, Veletri)

Epoprostenol (Flolan, Veletri) is covered for pulmonary arterial hypertension (WHO Group 1, FDA‑approved) and the compendial off‑label use chronic thromboembolic pulmonary hypertension (CTEPH) and is not authorized for other indications. Coverage requires PAH confirmed by right‑heart catheterization, prescription or consultation by a pulmonologist or cardiologist, NYHA class III–IV (or class II with current/prior trial of an oral PAH agent or prior inhaled/parenteral prostacyclin), for idiopathic PAH an acute vasodilator test during RHC (and if vasodilator‑responsive a trial of a calcium‑channel blocker unless contraindicated), documentation of ongoing benefit for reauthorization, approvals limited to 6 months with up to a 30‑day short‑term supply if criteria are unmet or information is insufficient.

"Documentation of New York Heart Association (NYHA) functional class (II, III, or IV)."